Related Experiment Video
Updated: May 20, 2026
08:43
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice
Published on: January 31, 2020
Infliximab in psoriatic arthritis
Fabrizio Cantini1, Laura Niccoli, Carlotta Nannini
1Department of Rheumatology, Hospital Misericordia e Dolce, Prato, Italy. fbrzcantini@gmail.com
The Journal of Rheumatology. Supplement
|July 4, 2012
Summary
Infliximab (IFX), an anti-tumor necrosis factor-α (TNF-α) drug, effectively treats psoriatic arthritis (PsA) and psoriasis. Clinical trials confirm its efficacy, safety, and ability to inhibit radiographic progression in PsA patients.
Area of Science:
- Immunology
- Rheumatology
- Dermatology
Background:
- Tumor necrosis factor-α (TNF-α) is a key factor in psoriasis and psoriatic arthritis (PsA) development.
- Anti-TNF-α therapies are recommended for PsA cases unresponsive to conventional treatments.
Purpose of the Study:
- To evaluate the efficacy and safety of infliximab (IFX), an anti-TNF-α biologic, in treating psoriatic arthritis (PsA).
Main Methods:
- Two randomized, placebo-controlled trials (IMPACT and IMPACT2) assessed IFX in PsA patients.
- Efficacy was measured by American College of Rheumatology (ACR) response criteria (ACR20, ACR50, ACR70) and psoriasis improvement.
- Radiographic progression and adverse events were also monitored.
Main Results:
- IFX treatment led to significant ACR20, ACR50, and ACR70 responses compared to placebo in both trials.
- Over 80% of IFX-treated patients showed psoriasis improvement, significantly more than placebo.
- IFX demonstrated inhibition of radiographic disease progression and was well-tolerated, with similar adverse event rates to placebo.
Conclusions:
- Infliximab (IFX) is an effective and safe treatment for psoriatic arthritis (PsA), improving joint and skin manifestations.
- Sustained efficacy and safety were observed during the extension phases of the trials.
- IFX offers a valuable therapeutic option for PsA patients resistant to traditional treatments.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:20Inflammatory Bowel Disease IV: Clinical Manifestations
Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...